AstraZeneca files Zactima for NSCLC in US and EU
31 July 2009
Katie McQue
Please Login to read the full article.
31 July 2009
Katie McQue
katie.mcque@informa.com
AstraZeneca has filed its oral targeted anticancer Zactima (vandetanib) with both the US FDA and the EMEA, for use in combination with chemotherapy as a second-line treatment for advanced non–small cell lung cancer (NSCLC).
Currently, standard second-line therapy in NSCLC consists...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Two-shots-on-goal deal gives Array best odds for $685M milestones in Genentech pact
- Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
- Lilly's Alimta blockbuster wins additional European approval
- Exelixis pained by FDA SPA no-show but pushes ahead with cabozantinib
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
